These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2438799)

  • 1. Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Dabhoiwala NF
    Thromb Haemost; 1987 Feb; 57(1):92-6. PubMed ID: 2438799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid.
    Hoek JA; Nurmohamed MT; Hamelynck KJ; Marti RK; Knipscheer HC; ten Cate H; Büller HR; Magnani HN; ten Cate JW
    Thromb Haemost; 1992 Jan; 67(1):28-32. PubMed ID: 1615479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of Org 10172, an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy.
    Gallus A; Murphy W; Nacey J; Morris M; Sutherland P; Marshall V; Magnani H
    Thromb Res; 1989 Oct; 56(2):229-38. PubMed ID: 2482549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs.
    Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR
    J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.
    Turpie AG; Levine MN; Hirsh J; Carter CJ; Jay RM; Powers PJ; Andrew M; Magnani HN; Hull RD; Gent M
    Lancet; 1987 Mar; 1(8532):523-6. PubMed ID: 2434815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial.
    Gerhart TN; Yett HS; Robertson LK; Lee MA; Smith M; Salzman EW
    J Bone Joint Surg Am; 1991 Apr; 73(4):494-502. PubMed ID: 1707413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis.
    Henny CP; ten Cate H; Surachno S; Stevens P; Büller HR; den Hartog M; ten Cate JW
    Thromb Haemost; 1985 Aug; 54(2):460-2. PubMed ID: 2417351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol.
    Stiekema JC; de Boer A; Danhof M; Kroon C; Broekmans AW; van Dinther TG; Voerman J; Breimer DD
    Haemostasis; 1990; 20(3):136-46. PubMed ID: 1696921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.
    Turpie AG; Gent M; Côte R; Levine MN; Ginsberg JS; Powers PJ; Leclerc J; Geerts W; Jay R; Neemeh J
    Ann Intern Med; 1992 Sep; 117(5):353-7. PubMed ID: 1503326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orgaran in the prevention of deep vein thrombosis in stroke patients.
    Turpie AG
    Haemostasis; 1992; 22(2):92-8. PubMed ID: 1379969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.
    De Boer A; Stiekema JC; Danhof M; Breimer DD
    Br J Clin Pharmacol; 1991 Jul; 32(1):23-9. PubMed ID: 1716140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Breimer DD
    J Clin Pharmacol; 1991 Jul; 31(7):611-7. PubMed ID: 1716644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
    Ortel TL; Gockerman JP; Califf RM; McCann RL; O'Connor CM; Metzler DM; Greenberg CS
    Thromb Haemost; 1992 Mar; 67(3):292-6. PubMed ID: 1379384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
    Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.
    Hobbelen PM; Vogel GM; Meuleman DG
    Thromb Res; 1987 Dec; 48(5):549-58. PubMed ID: 3481660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass.
    Doherty DC; Ortel TL; de Bruijn N; Greenberg CS; Van Trigt P
    Anesthesiology; 1990 Sep; 73(3):562-5. PubMed ID: 1697448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke.
    Biller J; Massey EW; Marler JR; Adams HP; Davis JN; Bruno A; Henriksen RA; Linhardt RJ; Goldstein LB; Alberts M
    Neurology; 1989 Feb; 39(2 Pt 1):262-5. PubMed ID: 2464774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.
    Bradbrook ID; Magnani HN; Moelker HC; Morrison PJ; Robinson J; Rogers HJ; Spector RG; Van Dinther T; Wijnand H
    Br J Clin Pharmacol; 1987 Jun; 23(6):667-75. PubMed ID: 3606928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.